Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two plant-based dietary supplements, Cinnamomum cassia (commonly known as cinnamon bark) and Withania somnifera (commonly known as ashwagandha). Both are widely used in traditional medicine systems. Cinnamomum cassia contains bioactive compounds such as cinnamaldehyde and coumarin, which have been reported to improve insulin sensitivity and help control blood sugar levels. Withania somnifera contains withanolides, alkaloids, and sitoindosides that exhibit adaptogenic, anti-inflammatory, antioxidant, neuroprotective, immunomodulatory, and metabolic effects. The combination has been studied for its potential to improve metabolic health and body composition in adults with overweight or obesity[1][2][3]. The mechanism of action is believed to involve modulation of glucose metabolism (via improved insulin sensitivity from Cinnamomum cassia) and reduction of stress hormones along with anti-inflammatory effects from Withania somnifera[4][5][6]. This supplement is not a pharmaceutical drug but rather a nutraceutical/dietary supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cinnamomum cassia + withania somnifera.